Altre lingue Ascelia Pharma AB

Azioni

ACE

SE0010573113

Mercato chiuso - Nasdaq Stockholm Altri mercati azionari 17:29:50 26/04/2024			Variaz. 5gg	Var. 1 gen.
11,16 ^SEK	+5,28%		-15,33%	+231,16%

10/04	Ascelia Pharma comunica il completamento della lettura delle immagini di SPARKLE e prevede risultati principali per la prima metà di maggio 2024	CI
09/02	Ascelia Pharma AB (publ) riporta i risultati degli utili per il quarto trimestre e l'intero anno terminato il 31 dicembre 2023	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Ascelia Pharma Draws Down SEK 15 Million Second Tranche Under Existing Loan Facility	18/04
Ascelia Pharma Reports SPARKLE Image Reading Completion and Expects Headline Results First Half of May 2024	10/04
Ascelia Pharma Reports SPARKLE Image Reading Completion and Expects Headline Results First Half of May 2024	10/04
Annual Report 2023: Solid Progress with Orviglance Phase 3 Patient Recruitment Completed and Headline Results Expected by May 2024	08/04
Notice of Annual General Meeting in Ascelia Pharma AB	27/03
Ascelia Pharma Q4 2023 - On track with easing financial pressure	12/02
Ascelia Pharma AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	09/02
Q4 and Full Year Report 2023: Strengthened Financial Position Ahead of SPARKLE Phase 3 Study Headline Results in May	09/02
Ascelia Pharma Secures Financing of up to SEK 35 Million	04/02
Orviglance Review Article Published in Investigative Radiology	24/01
Nomination Committee Appointed for AGM 2024 in Ascelia Pharma AB	24/01
Ascelia Pharma Announces Start of Image Reading Phase and Re-confirms Phase 3 SPARKLE Results by May 2024	07/12
Ascelia Pharma AB Announces Start of Image Reading Phase and Re- Confirms Phase 3 SPARKLE Results by May 2024	07/12
Change in Number of Shares and Votes in Ascelia Pharma AB	30/11
Bulletin from the Extraordinary General Meeting in Ascelia Pharma AB on 13 November 2023	13/11
Ascelia Pharma resolves on conversion of series C shares into ordinary shares for delivery to participants in incentive program	09/11
QUARTERLY REPORT Q3 2023: Re-evaluation of SPARKLE Phase 3 Study Images Progresses According to Plan	08/11
Ascelia Pharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	08/11
OptiCept Technologies Names New CFO	20/10/23
OptiCept Technologies recruits a new CFO	20/10/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Ascelia Pharma AB

Azioni

ACE

SE0010573113

Altre lingue

Filtri